BioMarin Acquires Inozyme, a Rare Disease Pharmaceutical Company, for $270 Million

BioMarin Acquires Inozyme, a Rare Disease Pharmaceutical Company, for $270 Million

BioMarin Acquires Inozyme, a Rare Disease Pharmaceutical Company, for $270 Million